news
Drugmakers try to dodge Trump-era rare disease price cuts
Rare disease drugmakers are trying to protect their products from potential Trump administration price cuts, despite the President's previous efforts to lower drug costs. Meanwhile, GOP voters are pushing for tougher action on healthcare fraud. There is ongoing concern about Pharmacy Benefit Managers (PBMs) finding ways around new state laws.
Rare disease drugmakers are trying to protect their products from potential Trump administration price cuts, despite the President's previous efforts to lower drug costs. Meanwhile, GOP voters are pushing for tougher action on healthcare fraud. There is ongoing concern about Pharmacy Benefit Managers (PBMs) finding ways around new state laws.
The architecture take
This isn't just about big pharma maneuvering; it's about what types of drug development get prioritized. When rare disease drugs are shielded from pricing scrutiny, it incentivizes more research and funding into treatments for conditions that might otherwise be overlooked. For you, it means if you or someone you know has a rare condition, there's more hope for new, albeit expensive, options. The flip side? This also means the cost burden often shifts, either to other parts of the healthcare system or directly to consumers through insurance premiums or out-of-pocket costs. Keep an eye on how these carve-outs influence future innovation – will it lead to breakthroughs, or just more creative pricing strategies? The fight over drug pricing is a constant game of whack-a-mole, and your wallet ultimately feels every hit.